Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption

Journal of Dermatological Science

Volumn 66, Issue 2, 2012, Pages 165-168

  Takata, Tomoya ^a   Tarutani, Masahito ^a   Sano, Shigetoshi ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

EGFR inhibitors; L Ascorbyl 2 phosphate; Papulopustular eruption; Sebaceous glands

Indexed keywords

ASCORBIC ACID 2 SULFATE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CELL IMMORTALIZATION; CELL INFILTRATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; FOLLICULITIS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; PAPULOPUSTULAR ERUPTION; PITUITARY STALK; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; REAL TIME POLYMERASE CHAIN REACTION; SEBACEOUS GLAND; SEBORRHEIC DERMATITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELLS, CULTURED; CYTOKINES; DRUG ERUPTIONS; HUMANS; KERATINOCYTES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEBACEOUS GLANDS;

EID: 84859773384     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.02.012     Document Type: Letter

References (10)

1. Dancey J., Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2:296-313.
2. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4:107-119.
3. Peus D., Hamacher L., Pittelkow M.R. EGF-receptor tyrosine kinase inhibition induces keratinocytes growth arrest and terminal differentiation. J Invest Dermatol 1997, 109:751-756.
4. Rodeck U., Jost M., Kari C., Shih D.T., Lavker R.M., Ewert D.L., et al. EGF-R-dependent regulation of keratinocytes survival. J Cell Sci 1997, 110:113-121.
5. Surguladze D., Deevi D., Claros N., Corcoran E., Wang S., Plym M.J., et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 2009, 69:5643-5647.
6. Guy R., Ridden C., Kealey T. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J Invest Dermatol 1996, 1096:454-460.
7. Xia L., Zouboulis C.C., Ju Q. Culture of human sebocytes in vitro. Dermatoendocrinology 2009, 1:92-95.
8. Zhang L., Li W.H., Anthonavage M., Eisinger M. Melanocortin-5 receptor: a marker of human sebocytes differentiation. Peptides 2006, 27:413-420.
9. Woolery-Lloyd H., Baumann L., Ikeno H. Sodium l-ascorbyl-2-phosphate 5% lotion for the treatment of acne vulgaris: a randomized, double-blind, controlled trial. J Cosmet Dermatol 2010, 9:22-27.
10. Boone S.L., Rademaker A., Liu D., Pfeiffer C., Mauro D.J., Lacouture M.E. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007, 72:152-159.